Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by John G Ullman & Associates Inc.

John G Ullman & Associates Inc. lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,555 shares of the medical research company’s stock after selling 450 shares during the period. Thermo Fisher Scientific comprises 1.2% of John G Ullman & Associates Inc.’s investment portfolio, making the stock its 22nd biggest position. John G Ullman & Associates Inc.’s holdings in Thermo Fisher Scientific were worth $7,878,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of TMO. Advisors Capital Management LLC increased its holdings in shares of Thermo Fisher Scientific by 5.8% in the 1st quarter. Advisors Capital Management LLC now owns 111,169 shares of the medical research company’s stock valued at $64,613,000 after acquiring an additional 6,089 shares during the last quarter. Cohen Capital Management Inc. increased its holdings in shares of Thermo Fisher Scientific by 0.4% in the 1st quarter. Cohen Capital Management Inc. now owns 56,999 shares of the medical research company’s stock valued at $33,128,000 after acquiring an additional 242 shares during the last quarter. Hemington Wealth Management increased its holdings in shares of Thermo Fisher Scientific by 6.1% in the 1st quarter. Hemington Wealth Management now owns 437 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 25 shares during the last quarter. Blue Square Asset Management LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $202,000. Finally, Team Hewins LLC increased its holdings in shares of Thermo Fisher Scientific by 0.7% in the 1st quarter. Team Hewins LLC now owns 3,171 shares of the medical research company’s stock valued at $1,844,000 after acquiring an additional 21 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The disclosure for this sale can be found here. Insiders sold a total of 22,000 shares of company stock valued at $12,532,780 over the last quarter. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO stock traded up $5.67 during midday trading on Thursday, hitting $542.54. 1,402,436 shares of the stock were exchanged, compared to its average volume of 1,541,105. The stock’s 50-day moving average price is $568.75 and its 200-day moving average price is $563.67. The stock has a market cap of $207.10 billion, a price-to-earnings ratio of 34.80, a PEG ratio of 2.50 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. Research analysts predict that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on TMO shares. JPMorgan Chase & Co. raised their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. The Goldman Sachs Group raised their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Deutsche Bank Aktiengesellschaft raised their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Barclays dropped their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research note on Friday, June 28th. Finally, Citigroup assumed coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They set a “neutral” rating and a $620.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $606.47.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.